BNP Paribas Initiates Coverage On West Pharmaceutical Servs with Outperform Rating, Announces Price Target of $447

Benzinga Newsdesk www.benzinga.com Positive 64.4%

Neg 0% Neu 0% Pos 64.4%

BNP Paribas analyst Curtis Moiles initiates coverage on West Pharmaceutical Servs (NYSE:WST) with a Outperform rating and announces Price Target of $447.